[Hypersensitivity to 5-aminosalicylic acid. Value of desensitization by oral route].
BACKGROUND
Treatment with sulphasalazine of patients with mild and moderate forms of Crohn's disease may result in side effects in some of them.


METHODS
An 11-year-old girl with Crohn's disease was given 40 mg/kd/day of sulphasalazine after achieving remission with prednisone. She developed urticaria and eosionophilia 8 days later, then extended skin edema during a second course of sulphasalazine requiring methyl prednisolone therapy. Mesalazine administration (25 mg/kg/day), one month later, resulted to watery stools, vomiting, and fever, a side effect observed again after two further mesalazine challenges of one-month interval. Eosionophilia was present and the lymphocyte stimulation test with mesalazine was positive. Successful desensitization to sulphasalazine could be obtained 9 months later permitting further safe administration of this drug up to 18 months.


CONCLUSIONS
Hypersensitivity to sulphasalazine may be successfully overcame by oral desensitization, especially in those patients with low-grade activity of Crohn's disease.
Lachaux
A
A
Unité d'hépatogastroentérologie et nutrition pédiatriques, hôpital Edouard-Herriot, Lyon, France.
Le Gall
C
C
Loras-Duclaux
I
I
Aboufadel
A
A
Hermier
M
M
D000284:Administration, Oral; D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy; D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D019804:Mesalamine; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; D012460:Sulfasalazine; D019804:Mesalamine
Hypersensibilité à l'acide 5-aminosalicylique. Intérêt de la désensibilisation par voie orale.